Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 4790810, 6 pages
https://doi.org/10.1155/2017/4790810
Review Article

Aprepitant for the Treatment of Chronic Refractory Pruritus

1Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
2Department of Anesthesiology, Duke University Medical Center, Durham, NC, USA

Correspondence should be addressed to Shawn G. Kwatra; moc.liamg@nwahs.artawk

Received 7 March 2017; Revised 20 April 2017; Accepted 14 August 2017; Published 19 September 2017

Academic Editor: Adam Reich

Copyright © 2017 Alice He et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Ständer and T. A. Luger, “NK-1 antagonists and itch,” Handbook of Experimental Pharmacology, vol. 226, pp. 237–255, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. C. L. Devane, “Substance P: A new era, a new role,” Pharmacotherapy, vol. 21, no. 9 I, pp. 1061–1069, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Patel and C. Lindley, “Aprepitant—a novel NK1 -receptor antagonist,” Expert Opinion on Pharmacotherapy, vol. 4, no. 12, pp. 2279–2296, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Duval and L. Dubertret, “Aprepitant as an antipruritic agent?” New England Journal of Medicine, vol. 361, no. 14, pp. 1415-1416, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Ständer, D. Siepmann, I. Herrgott, C. Sunderkötter, and T. A. Luger, “Targeting the neurokinin receptor 1 with aprepitant: A novel antipruritic strategy,” PLoS ONE, vol. 5, no. 6, Article ID e10968, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. B. Vincenzi, G. Tonini, and D. Santini, “Aprepitant for erlotinib-induced pruritus,” New England Journal of Medicine, vol. 363, no. 4, pp. 397-398, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Vincenzi, M. E. Fratto, D. Santini, and G. Tonini, “Aprepitant against pruritus in patients with solid tumours,” Supportive Care in Cancer, vol. 18, no. 9, pp. 1229-1230, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. O. Mir, B. Blanchet, and F. Goldwasser, “More on aprepitant for erlotinib-induced pruritus,” New England Journal of Medicine, vol. 364, no. 5, p. 487, 2011. View at Google Scholar · View at Scopus
  9. N. Booken, M. Heck, J. P. Nicolay, C. D. Klemke, S. Goerdt, and J. Utikal, “Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma,” British Journal of Dermatology, vol. 164, no. 3, pp. 665–667, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Torres, I. Fernandes, M. Selores, R. Alves, and M. Lima, “Aprepitant: Evidence of its effectiveness in patients with refractory pruritus continues,” Journal of the American Academy of Dermatology, vol. 66, no. 1, pp. e14–e15, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Santini, B. Vincenzi, F. M. Guida et al., “Aprepitant for management of severe pruritus related to biological cancer treatments: A pilot study,” The Lancet Oncology, vol. 13, no. 10, pp. 1020–1024, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Ladizinski, A. Bazakas, and E. A. Olsen, “Aprepitant: A novel neurokinin-1 receptor/substance P antagonist as antipruritic therapy in cutaneous T-Cell lymphoma,” Journal of the American Academy of Dermatology, vol. 67, no. 5, pp. e198–e199, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. M. S. Ally, C. S. Gamba, D. H. Peng, and J. Y. Tang, “The use of aprepitant in brachioradial pruritus,” JAMA Dermatology, vol. 149, no. 5, pp. 627-628, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Jiménez Gallo, C. Albarrán Planelles, M. Linares Barrios, M. J. Fernández Anguita, J. Márquez Enríquez, and M. E. Rodríguez Mateos, “Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant,” Dermatologic Therapy, vol. 27, no. 3, pp. 178–182, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. J. J. A. A. Villafranca, M. G. A. Siles, M. Casanova, B. T. Goitia, and A. R. U. Domínguez, “Paraneoplastic pruritus presenting with Hodgkin's lymphoma: a case report,” Journal of medical case reports, vol. 8, p. 300, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. I. Fernandes, T. Torres, M. Selores, R. Alves, and M. Lima, “Effectiveness of aprepitant,” Journal of Clinical and Experimental Dermatology Research, p. 149, 2012. View at Google Scholar
  17. J. W. Huh, Y.-I. Jeong, K.-H. Choi, H.-J. Park, and M.-S. Jue, “Treatment for refractory pruritus using oral aprepitant,” Annals of Dermatology, vol. 28, no. 1, pp. 124-125, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. J. S. Song, M. Tawa, N. G. Chau, T. S. Kupper, and N. R. LeBoeuf, “Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature,” BMC Cancer, vol. 17, no. 1, article no. 200, 2017. View at Publisher · View at Google Scholar · View at Scopus
  19. “EMEND (Aprepitant) [package insert]. Merck and Co, Inc., Whitehouse Station, NJ; March 2003,” http://www.merck.com/product/usa/pi_circulars/e/emend/emend_pi.pdf, 2015.
  20. M. S. Kramer, N. Cutler, J. Feighner et al., “Distinct mechanism for antidepressant activity by blockade of central substance P receptors,” Science, vol. 281, no. 5383, pp. 1640–1645, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Keller, S. Montgomery, W. Ball et al., “Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder,” Biological Psychiatry, vol. 59, no. 3, pp. 216–223, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Rakhit, M. P. Pantze, S. Fettner et al., “The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: Computer-based simulation (SimCYP™) predicts in vivo metabolic inhibition,” European Journal of Clinical Pharmacology, vol. 64, no. 1, pp. 31–41, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Wallengren, “Neuroanatomy and neurophysiology of itch,” Dermatologic Therapy, vol. 18, no. 4, pp. 292–303, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. T. A. Almeida, J. Rojo, P. M. Nieto et al., “Tachykinins and tachykinin receptors: structure and activity relationships,” Current Medicinal Chemistry, vol. 11, no. 15, pp. 2045–2081, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Andoh, T. Nagasawa, M. Satoh, and Y. Kuraishi, “Substance P induction of itch-associated response mediated by cutaneous NK1 tachykinin receptors in mice,” The Journal of Pharmacology and Experimental Therapeutics, vol. 286, no. 3, pp. 1140–1145, 1998. View at Google Scholar · View at Scopus
  26. M. Kulka, C. H. Sheen, B. P. Tancowny, L. C. Grammer, and R. P. Schleimer, “Neuropeptides activate human mast cell degranulation and chemokine production,” Immunology, vol. 123, no. 3, pp. 398–410, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Scholzen, C. A. Armstrong, N. W. Bunnett, T. A. Luger, J. C. Olerud, and J. E. Ansel, “Neuropeptides in the skin: Interactions between the neuroendocrine and the skin immune systems,” Experimental Dermatology, vol. 7, no. 2-3, pp. 81–96, 1998. View at Publisher · View at Google Scholar · View at Scopus
  28. S.-E. Chang, S.-S. Han, H.-J. Jung, and J.-H. Choi, “Neuropeptides and their receptors in psoriatic skin in relation to pruritus,” British Journal of Dermatology, vol. 156, no. 6, pp. 1272–1277, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. D. Weldon, “What lies beneath the surface of the itch in adults?” Allergy and Asthma Proceedings, vol. 28, no. 2, pp. 153–162, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Quartara and M. Altamura, “Tachykinin receptors antagonists: From research to clinic,” Current Drug Targets, vol. 7, no. 8, pp. 975–992, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Datar, S. Srivastava, E. Coutinho, and G. Govil, “Substance P: Structure, function, and therapeutics,” Current Topics in Medicinal Chemistry, vol. 4, no. 1, pp. 75–103, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Wallengren, “Topical aprepitant in clinical and experimental pruritus,” Archives of Dermatology, vol. 148, no. 8, pp. 957–959, 2012. View at Publisher · View at Google Scholar
  33. S. L. Chan, J. Jen, T. Burke, and J. Pellissier, “Economic analysis of aprepitant-containing regimen to prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Hong Kong,” Asia-Pacific Journal of Clinical Oncology, vol. 10, no. 1, pp. 80–91, 2014. View at Publisher · View at Google Scholar · View at Scopus